Search

Search Results

• FROM LEGACY TO INNOVATION: PIDOTIMOD’S EXPANDING THERAPEUTIC HORIZON Pidotimod: Revisiting a Classic Immunomodulator

  Claudio Ucciferri, Francesca Chiappini, Jacopo Vecchiet, Katia Falasca

  e2025057

  2025-08-31

  https://doi.org/10.4084/MJHID.2025.057

  3045

  PDF: 1058

  HTML: 1422

• Epidemiological surveillance of SARSCov2 in β-Thalassemia Patients in the last two years: reinfection rate, insights and future challenges

  Lorenza Torti, Francesco Sorrentino, Laura Maffei, Paolo De Fabritiis, Elisabetta Abruzzese

  e2023007

  2023-01-01

  https://doi.org/10.4084/MJHID.2023.007

  1251

  PDF: 1156

  HTML: 471

• Managment of Relapsed/Refractory ALL With Inotuzumab During COVID-19. A Casr Report

  Martina Di Palma, Elio Gentilini, Chiara Masucci, Alessandra Micozzi, Ombretta Turriziani, Antonino Mulè, Robin Foà, Maurizio Martelli, Gabriella D'Ettorre, Saveria Capria, Sabina Chiaretti

  e2022043

  2022-04-28

  https://doi.org/10.4084/MJHID.2022.043

  1744

  PDF: 627

  HTML: 256

• EFFICACY AND SAFETY OF SINOPHARM VACCINE FOR SARS-COV-2 AND BREAKTHROUGH INFECTIONS IN IRANIAN PATIENTS WITH HEMOGLOBINOPATHIES: A PRELIMINARY REPORT Sinopharm Vaccination in Iranian Patients with Hemoglobinopathies

  Mehran Karimi, Tahereh Zarei, Sezaneh Haghpanah , Azita Azarkeiva, Maryam Naderi , Sara Matin , Asghar Bazrafshan , Zohreh Zahedi , Afshan Shirkavand , Parisa pishdad, Vincenzo De Sanctis

  e2022026

  2022-02-27

  https://doi.org/10.4084/MJHID.2022.026

  1777

  PDF: 767

  HTML: 241

• Improving BNT162b2 mRNA vaccine tolerability without efficacy loss by Pidotimod supplementation Pidotimod in SARS-CoV-2 vaccination

  Claudio Ucciferri, Antonio Auricchio, Jacopo Vecchiet, Katia Falasca

  e2022023

  2022-02-27

  https://doi.org/10.4084/MJHID.2022.023

  2244

  PDF: 595

  HTML: 282